If you scroll down on the left side, there is an article and you can click on it. BUT, there is no direct link. ?]
So, anyway, here is the article:
not dated, but appears to be July 1, 2011
YESTERDAY by ■ Michael Krebs - comments
Op-Ed: An FDA Avastin rejection is a window on Obamacare redistribution
The FDA’s pending rejection of the late-stage breast cancer drug Avastin offers a window on an Obamacare wealth redistribution, effectively putting less value on sick American women than on people in foreign nations receiving US monetary or military aid.
According to a Reuters report on Wednesday, the cumulative cost of the wars in Iraq, Afghanistan and Pakistan to the American taxpayer is estimated at $3.7 trillion and climbing. These wars are effectively investments by the US government in the future security of these nations, and similar investments are being made in Libya and Yemen currently.
Similarly, according to Vaughn’s Summaries, the United States continues to commit monetarily to foreign governments, with Israel and Egypt consistently receiving billions. In 2011, the US government has pledged fresh financial support for Tunisia, Egypt, Pakistan, and Libya.
Additionally, the US military operates large non-combat bases in Japan, South Korea, Germany, Eastern Europe, and the Middle East.
These foreign investments exist, and have existed, throughout the financial crisis that has decimated the US economy over the past few years, a period of time known as The Great Recession. The US national debt is broadly seen as unsustainable, and US politicians in both political parties are now openly discussing the demise of many entitlement programs common to American citizens.
Social Security and Medicare are on the chopping block, but foreign monetary and military aid is not.
And now the prospect of health care rationing under President Obama’s health care legislation has just this week presented itself.
Avastin is a late-stage chemotherapy drug for women in the final throes of breast cancer. It is a drug that represents experimentation and innovation in medicine and that offers a frontier understanding of what is possible in modern biochemistry.
However, according to the Washington Post, Avastin costs roughly $88,000 per year per patient to administer.
It has been argued by the US Food and Drug Administration panel of “experts” that Avastin poses more of a danger than it does a benefit. Yet, The American Spectator notes that Europe’s similar governmental body of health experts, the European Medicines Agency, came to a remarkably different conclusion, recommending that Avastin treatment be expanded.
The FDA and EMA recommendations on Avastin represent very divergent conclusions. European women hold more value to Europe’s government agency than American women hold to the US federal government.
Great societies are judged to be great by the manner in which they treat their women and children.
The Avastin rejection is a health care rationing issue, and it is a decision made on financial grounds. This is Obamacare’s ugly underbelly, and it is real.
The Avastin rejection is a death sentence for women who need more than hope. The rejection of this drug in the backdrop of US investment elsewhere around the world is an effective way of saying quite loudly that the rest of the world’s citizens matter more than our own women.
An American woman is not worth $88,000 a year, but trillions can be distributed elsewhere.
Read more: digitaljournal.com/article/308614#ixzz1Qzs05aY4